SecurityCVO / Cenveo, Inc. (15670S105)
IndustryConverted Paper And Paperboard Products, Except
Institutional Owners6
Institutional Shares3,136,440 - 36.55%
Common Shares Outstanding8,581,964 shares (as of 2017-09-30)
Institutional Value$ 10,159,000 USD
Related 15671BAE1 / Cenveo Corp. 8.875% 02/01/18
CVOVQ / Cenveo Inc
15671BAK7 / Cenveo, Inc. Bond
15671BAL5 / Cenveo, Inc. Bond
15671BAG6 / Cenveo, Inc. Bond
15671BAJ0 / Cenveo, Inc. Bond

Institutional Stock Ownership and Shareholders

CVO / Cenveo, Inc. Institutional Ownership

Cenveo, Inc. (NASDAQ:CVO) has 6 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,136,440 shares. Largest shareholders include Allianz Global Investors U.S. Holdings LLC, Rotation Capital Management, LP, BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, BlackRock Advisors LLC, and BlackRock Investment Management, LLC.
Cenveo, Inc. (NASDAQ:CVO) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-02-14 13F-HR Zelman Capital LLC 487,531 0 -100.00 3,437 0 -100.00
2018-08-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 22,062 0 -100.00 1 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 17,830 18,534 3.95 126 130 3.17
2017-08-14 13F-HR/A Rotation Capital Management, LP 1,426,782 1,378,744 -3.37 7,162 8,397 17.24
2018-04-18 13F-HR/A FNY Managed Accounts LLC 3,200 0 -100.00 2 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 1,842 1,842 0.00 13 13 0.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 1,293 1,293 0.00 9 9 0.00
2017-02-14 SC 13G Allianz Global Investors U.S. Holdings LLC 15,965,301 1,505,696 -90.57
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 0 230,331 0.00 0 1,610 -0.86

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

19h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

Related News Stories

Assessing Main Street Capital's Results For Q1 2018 (Includes Investment Rating Analysis)

2018-05-09 seekingalpha
This article assesses MAIN’s performance for Q1 2018 and compares results over the trailing twelve months. (23-3)

CUSIP: 15670S105